170 related articles for article (PubMed ID: 35613082)
1. A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.
Logan A; Nagy Z; Barnes NM; Belli A; Di Pietro V; Tavazzi B; Lazzarino G; Lazzarino G; Bruce L; Persson LI
PLoS One; 2022; 17(5):e0267183. PubMed ID: 35613082
[TBL] [Abstract][Full Text] [Related]
2. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis.
Logan A; Belli A; Di Pietro V; Tavazzi B; Lazzarino G; Mangione R; Lazzarino G; Morano I; Qureshi O; Bruce L; Barnes NM; Nagy Z
Front Pharmacol; 2022; 13():983853. PubMed ID: 36110516
[No Abstract] [Full Text] [Related]
4. ILB
Lazzarino G; Mangione R; Belli A; Di Pietro V; Nagy Z; Barnes NM; Bruce L; Ropero BM; Persson LI; Manca B; Saab MW; Amorini AM; Tavazzi B; Lazzarino G; Logan A
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442438
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
6. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Gotkine M; Caraco Y; Lerner Y; Blotnick S; Wanounou M; Slutsky SG; Chebath J; Kuperstein G; Estrin E; Ben-Hur T; Hasson A; Molakandov K; Sonnenfeld T; Stark Y; Revel A; Revel M; Izrael M
J Transl Med; 2023 Feb; 21(1):122. PubMed ID: 36788520
[TBL] [Abstract][Full Text] [Related]
8. Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Salomon-Zimri S; Pushett A; Russek-Blum N; Van Eijk RPA; Birman N; Abramovich B; Eitan E; Elgrart K; Beaulieu D; Ennist DL; Berry JD; Paganoni S; Shefner JM; Drory VE
Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):263-271. PubMed ID: 36106817
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
10. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
11. Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial.
Yamashita T; Nakano Y; Sasaki R; Tadokoro K; Omote Y; Yunoki T; Kawahara Y; Matsumoto N; Taira Y; Matsuoka C; Morihara R; Abe K
Cell Transplant; 2023; 32():9636897231214370. PubMed ID: 38014622
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
[TBL] [Abstract][Full Text] [Related]
13. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
15. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Babu S; Hightower BG; Chan J; Zürcher NR; Kivisäkk P; Tseng CJ; Sanders DL; Robichaud A; Banno H; Evora A; Ashokkumar A; Pothier L; Paganoni S; Chew S; Dojillo J; Matsuda K; Gudesblatt M; Berry JD; Cudkowicz ME; Hooker JM; Atassi N
Neuroimage Clin; 2021; 30():102672. PubMed ID: 34016561
[TBL] [Abstract][Full Text] [Related]
16. Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis.
Li X; Koeberl DD; Lutz MW; Bedlack R
J Clin Neuromuscul Dis; 2023 Jun; 24(4):214-221. PubMed ID: 37219865
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis.
Walk D; Nicholson K; Locatelli E; Chan J; Macklin EA; Ferment V; Manousakis G; Chase M; Connolly M; Dagostino D; Hall M; Ostrow J; Pothier L; Lieberman C; Gelevski D; Randall R; Sherman AV; Steinhart E; Walker DG; Walker J; Yu H; Wills AM; Schwarzschild MA; Beukenhorst AL; Onnela JP; Berry JD; Cudkowicz ME; Paganoni S
Muscle Nerve; 2023 May; 67(5):378-386. PubMed ID: 36840949
[TBL] [Abstract][Full Text] [Related]
18. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.
Lingor P; Weber M; Camu W; Friede T; Hilgers R; Leha A; Neuwirth C; Günther R; Benatar M; Kuzma-Kozakiewicz M; Bidner H; Blankenstein C; Frontini R; Ludolph A; Koch JC;
Front Neurol; 2019; 10():293. PubMed ID: 30972018
[No Abstract] [Full Text] [Related]
19. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
